Welcome to our dedicated page for Kalaris Therapeutics news (Ticker: KLRS), a resource for investors and traders seeking the latest updates and insights on Kalaris Therapeutics stock.
Kalaris Therapeutics, Inc. (NASDAQ: KLRS) is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). News about Kalaris often centers on the progress of its lead investigational therapy, TH103, a fully humanized recombinant fusion protein designed as an anti-VEGF decoy receptor with features intended to enhance VEGF inhibition and intraocular retention.
Investors and observers following KLRS news can expect regular updates on the TH103 clinical program. These include announcements of enrollment and design changes for Phase 1 and Phase 1b/2 trials in treatment-naïve nAMD patients, initial safety, pharmacokinetic, and preliminary efficacy data, and company commentary on how early clinical findings align with TH103’s molecular design and preclinical profile. Kalaris also issues news releases when it presents data or corporate overviews at healthcare and emerging growth equity conferences.
Another recurring theme in Kalaris news is corporate and financial development. The company reports quarterly financial results, highlighting research and development spending, cash and investment balances, and runway expectations based on its operating plans. It also discloses leadership changes, such as the appointment of senior clinical and financial executives, and capital-raising activities like private placements of common stock and pre-funded warrants with institutional investors.
This KLRS news page aggregates these company communications, providing a centralized view of clinical milestones, financing transactions, governance updates, and investor events related to Kalaris Therapeutics’ efforts to advance TH103 and its broader retinal disease program.
Kalaris Therapeutics (NASDAQ: KLRS), a clinical-stage biopharmaceutical company focused on retinal disease treatments, announced its participation in the Stifel 2025 Virtual Ophthalmology Forum. The company's management, including CEO Andrew Oxtoby and CMO Matthew Feinsod, will engage in a Fireside Chat on Tuesday, May 27th, 2025, at 8:00 AM ET. A replay of the event will be available on the company's Investor Relations webpage.
Kalaris Therapeutics (NASDAQ: KLRS) reported its Q1 2025 financial results and provided business updates. The company is advancing its Phase 1 trial of TH103, a novel anti-VEGF treatment for neovascular age-related macular degeneration (nAMD). Initial clinical data is expected in Q4 2025.
Financial highlights include cash and cash equivalents of $101.0 million as of March 31, 2025, up from $1.6 million in December 2024, primarily due to the AlloVir merger. The company reported a net loss of $10.2 million ($2.52 per share) compared to $3.4 million ($2.60 per share) in Q1 2024. R&D expenses increased to $6.0 million from $2.0 million, while G&A expenses rose to $4.3 million from $0.6 million year-over-year.
Kalaris Therapeutics (NASDAQ: KLRS), a clinical-stage biopharmaceutical company focused on retinal disease treatments, has appointed Leone Patterson to its Board of Directors and as Chair of the Board's Audit Committee. Patterson currently serves as Executive Vice President, Chief Business Officer and Chief Financial Officer at Zymeworks, managing corporate finance, business development, and operations.
Patterson brings extensive biotech industry experience, having previously held leadership positions at Tenaya Therapeutics as Chief Financial and Business Officer, and at Adverum Biotechnologies as CFO, President, CEO, and Director. Her career includes senior finance roles at Diadexus, Transcept, Exelixis, Novartis, and Chiron, as well as experience in KPMG's audit practice. She holds a B.S. in business administration and accounting from Chapman University and an executive MBA from St. Mary's College.
Kalaris Therapeutics (NASDAQ: KLRS) has completed its merger with AlloVir, with shares set to trade on Nasdaq from March 19, 2025. The company's focus is on developing TH103, a novel anti-VEGF treatment for retinal diseases, specifically engineered to address limitations in current neovascular Age-related Macular Degeneration (nAMD) therapies.
The clinical-stage biopharmaceutical company's lead candidate has shown promising preclinical results with potent anti-VEGF activity and sustained ocular residence time. Initial data from Part 1 of the ongoing Phase 1 trial in nAMD patients is expected in H2 2025.
Following the merger, Kalaris has approximately $100 million in cash and cash equivalents, projected to fund operations into Q4 2026, extending beyond the planned Phase 2 clinical trial initiation.